Entera Bio Ltd
Research Entera Bio Ltd (ENTX) on Bullrun: market cap USD 171.04M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerENTX
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 171.04M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 7.31M
- Free cash flow-USD 3.47M
Valuation Snapshot
latest market cap is USD 171.04M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 42.00K | -USD 11.44M | -USD 7.48M | 0.0% | 0.25 | USD 7.11M | USD 490.00K | USD 13.10M |
| FY2024 | USD 181.00K | -USD 9.54M | -USD 6.82M | 5.0% | 0.25 | USD 8.66M | USD 272.00K | USD 8.08M |
| FY2023 | USD 0 | -USD 8.89M | -USD 7.33M | n/a | 0.31 | USD 11.02M | USD 390.00K | USD 10.39M |
| FY2022 | USD 134.00K | -USD 13.07M | -USD 12.55M | 24.6% | 0.45 | USD 12.31M | USD 177.00K | USD 11.75M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 171.04M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 89.59M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 82.33M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 22.04M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 21.03M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 81.23M | n/a | n/a | n/a |
About Entera Bio Ltd
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Entera Bio Ltd's market cap?
Entera Bio Ltd's market capitalization is USD 171.04M.
What does Entera Bio Ltd do?
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.